Assessment of preference for breast cancer chemoprevention in Japanese young women.
Pills containing estrogen and progesterone or gonadotropin releasing hormone agonist have been considered valuable to prevent breast cancer. This study assessed preference for the combination-type pill for preventing breast cancer, to evaluate the hypothetical preventive effect of this agent among young Japanese women. The standard gamble method was applied. Fifty-five college students and 44 nursing school students aged between 18 and 41 years were asked to decide the probability of being affected by breast cancer at which they would start to take this agent. Preference score was calculated by subtracting the probability given by each respondent from 1, which corresponds to the value (utility) she allotted to the agent. The means of preference score were 0.58, 0.48, 0.37, and 0.27 for 100, 75, 50, and 25% of efficacy levels of the agent, respectively. Preference score was significantly lower in nursing school students and those whose knowledge about hormones were relatively high. Score of Health Locus of Control (HLC) was nonsignificantly negatively correlated with preference score at any efficacy level. HLC score was significantly higher among those who refused the agent with 50 and 25% efficacy levels at 100% level of breast cancer risk. The data suggest that perceived risk of this agent was not negligibly small in this population and school status, knowledge about hormones, and beliefs about health would affect preference for the agent. Understanding of preference for chemopreventive agents for breast cancer, especially those containing hormones, is important to assess their potential as future preventive agents and is helpful when planning a strategy of chemoprevention.
Nagata
C
C
Department of Public Health, Gifu University School of Medicine.
D000293:Adolescent; D000328:Adult; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001294:Attitude to Health; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D018890:Chemoprevention; D003258:Consumer Behavior; D004338:Drug Combinations; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007389:Internal-External Control; D007564:Japan; D011374:Progesterone / Q000627:therapeutic use; D012307:Risk Factors; D013334:Students; D013338:Students, Nursing; D014495:Universities
D016588:Anticarcinogenic Agents; D004338:Drug Combinations; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone